Hong Ting-Ting, Huang Jinbao, Barrett Terrance D, Lucchesi Benedict R
Department of Pharmacology, University of Michigan Medical School, 1150 W. Medical Center Drive, Ann Arbor, MI 48109-0632, USA.
Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H145-55. doi: 10.1152/ajpheart.00646.2007. Epub 2007 Oct 5.
This study was designed to determine the effect of inhibitors of cyclooxygenase (COX)-1, COX-2, and the nonselective COX inhibitor naproxen on coronary vasoactivity and thrombogenicity under baseline and lipopolysaccharide (LPS)-induced inflammatory conditions. We hypothesize that endothelial COX-1 is the primary COX isoform in the canine normal coronary artery, which mediates arachidonic acid (AA)-induced vasodilatation. However, COX-2 can be induced and overexpressed by inflammatory mediators and becomes the major local COX isoform responsible for the production of antithrombotic prostaglandins during systemic inflammation. The interventions included the selective COX-1 inhibitor SC-560 (0.3 mg/kg iv), the selective COX-2 inhibitor nimesulide (5 mg/kg iv), or the nonselective COX inhibitor naproxen (3 mg/kg iv). The selective prostacyclin (IP) receptor antagonist RO-3244794 (RO) was used as an investigational tool to delineate the role of prostacyclin (PGI(2)) in modulating vascular reactivity. AA-induced vasodilatation of the left circumflex coronary artery was suppressed to a similar extent by each of the COX inhibitors and RO. The data suggest that AA-induced vasodilatation in the normal coronary artery is mediated by a single COX isoform, the constitutive endothelial COX-1, which is reported to be susceptible to COX-2 inhibitors. The effect of the COX inhibitors on thrombus formation was evaluated in a model of carotid artery thrombosis secondary to electrolytic-induced vessel wall injury. Pretreatment with LPS (0.5 mg/kg iv) induced a systemic inflammatory response and prolonged the time-to-occlusive thrombus formation, which was reduced in the LPS-treated animals by the administration of nimesulide. In contrast, neither SC-560 nor naproxen influenced the time to thrombosis in the animals pretreated with LPS. The data are of significance in view of reported adverse cardiovascular events observed in clinical trials involving the use of selective COX-2 inhibitors, thereby suggesting that the endothelial constitutive COX-1 and the inducible vascular COX-2 serve important functions in maintaining vascular homeostasis.
本研究旨在确定环氧合酶(COX)-1、COX-2抑制剂以及非选择性COX抑制剂萘普生在基线和脂多糖(LPS)诱导的炎症条件下对冠状动脉血管活性和血栓形成性的影响。我们假设内皮COX-1是犬正常冠状动脉中的主要COX同工型,它介导花生四烯酸(AA)诱导的血管舒张。然而,COX-2可被炎症介质诱导并过度表达,并在全身炎症期间成为负责产生抗血栓前列腺素的主要局部COX同工型。干预措施包括选择性COX-1抑制剂SC-560(0.3mg/kg静脉注射)、选择性COX-2抑制剂尼美舒利(5mg/kg静脉注射)或非选择性COX抑制剂萘普生(3mg/kg静脉注射)。选择性前列环素(IP)受体拮抗剂RO-3244794(RO)用作研究工具,以阐明前列环素(PGI₂)在调节血管反应性中的作用。每种COX抑制剂和RO对AA诱导的左旋冠状动脉血管舒张的抑制程度相似。数据表明,正常冠状动脉中AA诱导的血管舒张由单一的COX同工型即组成型内皮COX-1介导,据报道该同工型对COX-2抑制剂敏感。在电解诱导的血管壁损伤继发的颈动脉血栓形成模型中评估了COX抑制剂对血栓形成的影响。用LPS(0.5mg/kg静脉注射)预处理可诱导全身炎症反应并延长闭塞性血栓形成时间,在LPS处理的动物中,给予尼美舒利可缩短该时间。相比之下,SC-560和萘普生均未影响用LPS预处理的动物的血栓形成时间。鉴于在涉及使用选择性COX-2抑制剂的临床试验中观察到的不良心血管事件报道,这些数据具有重要意义,从而表明内皮组成型COX-1和诱导性血管COX-2在维持血管稳态中发挥重要作用。